Cstone Pharmaceuticals
About
8.05HKD+0.44 +5.78%
Closed • Updated at 03:59 GMT+00:00Market Cap$1.53B
Volume11.18M
Beta0.85
RSI46.05
Gross Margin4.06%
Cstone Pharmaceuticals — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 20 2026
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
Feb 23 2026
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
Feb 16 2026
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
Nov 7 2025
ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
Oct 20 2025
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Recent Videos
Cstone Pharmaceuticals 2026 latest report
Apr 28, 2026
Cstone Pharmaceuticals 2025 annual report
Mar 29, 2026
🚀基石药业(2616.HK)：生物科技突破，解锁价值！#2616HK #肿瘤创新药 @trade247s #lulu日股夜股记
Nov 11, 2025
CSTONE PHARMA-B 2025 interim report
Sep 30, 2025
Community Chat
Ask AI
Try asking